Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




German Partners to Develop Biomarker Platform for Targeted Cellular Therapies

By LabMedica International staff writers
Posted on 05 Mar 2012
Two German biotech companies are cooperating in a personalized medicine project to develop a predominantly tissue-based biomarker strategy for the treatment of solid cancers with cellular and / or gene therapeutics.

The partnership will exploit the complimentary assets of apceth GmbH & Co. More...
KG (Munich, Germany), and Indivumed GmbH, (Hamburg, Germany). apceth is known for its development and clinical application of pioneering stem cell and gene therapies, particularly for the treatment of malignant diseases. Indivumed maintains a comprehensive tumor database and high-quality biobank for the development of new cancer diagnostics and therapies, and provides state-of-the-art services for biomarker discovery based on viable primary human biospecimens.

The goal of the new project is to predict the response to targeted cellular/ gene therapy in different cancer types and to stratify patients to provide a more individualized cancer treatment with apceth’s innovative cell and cell-based gene therapeutics.

The partners have indicated that the combination of apceth’s therapeutic approach and Indivumed’s biomarker platform has the potential to drive future cancer therapeutics and pharmaceutical innovation, thereby making the promises for personalized medicine a reality.

Related Links:
apceth GmbH & Co. KG
Indivumed GmbH




Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.